Neuronal Ceroid Lipofuscinoses: Connecting Calcium Signalling through Calmodulin
Related Experiment Video
Updated: Feb 3, 2026

Pull-down of Calmodulin-binding Proteins
Published on: January 23, 2012
Sabateeshan Mathavarajah1, Danton H O'Day2,3, Robert J Huber4
1Department of Pathology, Dalhousie University, Halifax, NS B3H 4R2, Canada. smathavarajah@trentu.ca.
Abstract:
Despite the increased focus on the role of calcium in the neuronal ceroid lipofuscinoses (NCLs, also known as Batten disease), links between calcium signalling and the proteins associated with the disease remain to be identified. A central protein in calcium signalling is calmodulin (CaM), which regulates many of the same cellular processes affected in the NCLs. In this study, we show that 11 of the 13 NCL proteins contain putative CaM-binding domains (CaMBDs). Many of the missense mutations documented from NCL patients overlap with the predicted CaMBDs and are often key residues of those domains. The two NCL proteins lacking such domains, CLN7 and CLN11, share a commonality in undergoing proteolytic processing by cathepsin L, which contains a putative CaMBD. Since CaM appears to have both direct and indirect roles in the NCLs, targeting it may be a valid therapeutic approach for treating the disease.
Insights
Researchers found that most neuronal ceroid lipofuscinoses (NCLs) proteins bind to calmodulin, a key calcium-signaling molecule. Mutations in these binding sites may contribute to Batten disease, suggesting calmodulin as a therapeutic target.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Neuronal ceroid lipofuscinoses (NCLs), or Batten disease, are a group of rare genetic disorders affecting the nervous system.
- Calcium signaling is increasingly recognized as a critical factor in NCL pathogenesis.
- Calmodulin (CaM) is a central mediator of calcium signaling, regulating numerous cellular processes implicated in NCLs.
Purpose of the Study:
- To investigate the potential links between calcium signaling, specifically calmodulin, and the proteins associated with NCLs.
- To identify if NCL-associated proteins possess calmodulin-binding domains (CaMBDs) and if disease-causing mutations affect these interactions.
Main Methods:
- Bioinformatic analysis to identify putative CaMBDs in NCL proteins.
- Comparison of known NCL patient mutations with predicted CaMBDs.
- Analysis of NCL proteins lacking CaMBDs and their interaction with cathepsin L.
Main Results:
- 11 out of 13 NCL proteins were found to contain putative CaM-binding domains.
- Many missense mutations found in NCL patients overlap with these predicted CaMBDs, affecting key residues.
- The NCL proteins CLN7 and CLN11, which lack CaMBDs, are processed by cathepsin L, an enzyme possessing a CaMBD.
Conclusions:
- Calmodulin likely plays both direct and indirect roles in the pathophysiology of NCLs.
- The direct and indirect interactions suggest that targeting calmodulin could be a viable therapeutic strategy for Batten disease.
Related Concept Videos
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
What is Cell Signaling?
Synaptic Signaling
Dietary Connections
Cell-surface Signaling
Introduction to Connective Tissues

